- Home
- SGC vs ELDN Comparison
SGC vs ELDN Comparison
Compare SGC & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGC
- ELDN
- Stock Information
- Founded
- SGC 1920
- ELDN 2004
- Country
- SGC United States
- ELDN United States
- Employees
- SGC N/A
- ELDN N/A
- Industry
- SGC Apparel
- ELDN Biotechnology: Pharmaceutical Preparations
- Sector
- SGC Consumer Discretionary
- ELDN Health Care
- Exchange
- SGC Nasdaq
- ELDN Nasdaq
- Market Cap
- SGC 281.4M
- ELDN 288.5M
- IPO Year
- SGC N/A
- ELDN N/A
- Fundamental
- Price
- SGC $14.45
- ELDN $4.29
- Analyst Decision
- SGC Strong Buy
- ELDN Strong Buy
- Analyst Count
- SGC 2
- ELDN 1
- Target Price
- SGC $22.50
- ELDN $16.00
- AVG Volume (30 Days)
- SGC 40.0K
- ELDN 232.7K
- Earning Date
- SGC 03-12-2025
- ELDN 03-27-2025
- Dividend Yield
- SGC 3.88%
- ELDN N/A
- EPS Growth
- SGC 79.86
- ELDN N/A
- EPS
- SGC 0.82
- ELDN N/A
- Revenue
- SGC $567,509,000.00
- ELDN N/A
- Revenue This Year
- SGC $5.29
- ELDN N/A
- Revenue Next Year
- SGC $3.87
- ELDN N/A
- P/E Ratio
- SGC $17.64
- ELDN N/A
- Revenue Growth
- SGC 4.19
- ELDN N/A
- 52 Week Low
- SGC $11.66
- ELDN $1.52
- 52 Week High
- SGC $21.80
- ELDN $5.54
- Technical
- Relative Strength Index (RSI)
- SGC 37.35
- ELDN 44.28
- Support Level
- SGC $14.31
- ELDN $4.40
- Resistance Level
- SGC $15.05
- ELDN $4.65
- Average True Range (ATR)
- SGC 0.41
- ELDN 0.23
- MACD
- SGC -0.01
- ELDN -0.04
- Stochastic Oscillator
- SGC 14.00
- ELDN 8.16
About SGC Superior Group of Companies Inc.
Superior Group Of Companies Inc designs apparel products. The company's operating segment includes Branded Products; Healthcare Apparel and Contact Centers. It generates maximum revenue from the Branded Products segment. The Branded Products segment produce and sell customized merchandising solutions, promotional products and branded uniform programs to customers.
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS. The company's compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.